Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.

Kim H Kwan; Ingrid JG Burvenich; Margaret M Centenera; Yit Wooi Goh; Angela Rigopoulos; Jonas Dehairs; Johannes V Swinnen; Ganesh V Raj; Andrew J Hoy; Lisa M Butler; Andrew M Scott; Jonathan M White; Uwe Ackermann

Journal article

Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.

Kim H Kwan, Ingrid JG Burvenich, Margaret M Centenera, Yit Wooi Goh, Angela Rigopoulos, Jonas Dehairs, Johannes V Swinnen, Ganesh V Raj, Andrew J Hoy, Lisa M Butler, Andrew M Scott, Jonathan M White, Uwe Ackermann

Nuclear Medicine and Biology | Elsevier | Published : 2020

DOI: 10.1016/j.nucmedbio.2020.11.007

Abstract

INTRODUCTION: Altered lipid metabolism and subsequent changes in cellular lipid composition have been observed in prostate cancer cells, are associated with poor clinical outcome, and are promising targets for metabolic therapies. This study reports for the first time on the synthesis of a phospholipid radiotracer based on the phospholipid 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine (PC44:12) to allow tracking of polyunsaturated lipid tumor uptake via PET imaging. This tracer may aid in the development of strategies to modulate response to therapies targeting lipid metabolism in prostate cancer. METHODS: Lipidomics analysis of prostate tumor explants and LNCaP tumor cells were used to ..

View full abstract

University of Melbourne Researchers

Andrew Scott Author Medicine - Austin Health

Jonathan White Author Chemistry

Uwe Ackermann Author Medicine - Austin Health

Grants

Awarded by National Cancer Institute of the National Institutes of Health

Awarded by Research Foundation Flanders

Awarded by KU Leuven

Awarded by Australian Research Council Future Fellowship

Awarded by Beat Cancer SA Beat Cancer Project Principal Cancer Research Fellowship

Awarded by NHRMC Senior Investigator grant

Awarded by Interreg V -A

Funding Acknowledgements

We acknowledge the Australian Cancer Research Foundation for providing funds to purchase the nanoPET/MRI and nanoSPECT/CT imaging equipment. We utilized the services of the Simmons Cancer Center's Tissue Management Shared Resource at UT Southwestern Medical Center at Dallas. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA142543. This research was also undertaken using the Solid Target Laboratory, an ANSTO-Austin-LICR Partnership and with the support of the Operational Infrastructure Support Program of the Victorian State Government. We also acknowledge the use of the Melbourne Mass Spectrometry and Proteomics Facility (MMSPF) of the Bio21 Molecular Science and Biotechnology Institute at The University of Melbourne for the support of mass spectrometry analysis. AJH is supported by a Robinson Fellowship and funding from the University of Sydney. JVS is supported by the Research Foundation Flanders (FWO G.0841.15 to JVS), the Stichting tegen Kanker (to JVS), KU Leuven (C16/15/073 and C32/17/052 to JVS), Interreg V -A (EMR23 "EURLIPIDS"). LMB was supported by an Australian Research Council Future Fellowship (130101004), and a Beat Cancer SA Beat Cancer Project Principal Cancer Research Fellowship (PRF1117). AMS was supported by an NHRMC Senior Investigator grant (1177837). LMB, JVS, AS, and AJH are supported by the Movember Foundation and the Prostate Cancer Foundation of Australia (MRTA3). GVR is supported by the Prostate Cancer Foundation (US) and the US Department of Defense.